Literature DB >> 26457728

Historical perspective and contemporary management of acute coronary syndromes: from MONA to THROMBINS2.

Kristopher P Kline1, C Richard Conti2, David E Winchester2.   

Abstract

Acute coronary syndrome (ACS) remains a major burden on morbidity and mortality in the United States. Medical professionals and students often use the mnemonic 'MONA' (morphine, oxygen, nitroglycerin and aspirin) to recall treatments for ACS; however, this list of therapies is outdated. We provide a historical perspective on 'MONA,' attempt to uncover its origin in the medical literature, and demonstrate the myriad changes that have occurred over the last 50 years of ACS management. We have developed a novel mnemonic, 'THROMBINS2' (thienopyridines, heparin/enoxaparin, renin-angiotensin system blockers, oxygen, morphine, beta blocker, intervention, nitroglycerin, statin/salicylate) to help bedside clinicians recall all the elements of contemporary ACS management. We demonstrate the mortality benefit for each component of contemporary ACS management, correlating the continued improvement with historical data on mortality after myocardial infarction. We encourage providers to utilize this mnemonic to explore options and guide treatments in ACS patients.

Entities:  

Keywords:  Acute myocardial infarction; ST-elevation myocardial infarction; acute coronary syndrome; coronary artery disease; non-ST-elevation myocardial infarction; unstable angina

Mesh:

Substances:

Year:  2015        PMID: 26457728     DOI: 10.1080/00325481.2015.1092374

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  1 in total

1.  The Improvement of Cardiac and Endothelial Functions of Xue-Fu-Zhu-Yu Decoction for Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Shiqi Chen; Xiaoxiao Wu; Tong Li; Weiting Cheng; Xiaowan Han; Yang Li; Baofu Wang; Yu Teng; Mingjing Zhao; Yahong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-10       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.